Details for New Drug Application (NDA): 206815
✉ Email this page to a colleague
NDA 206815 describes SODIUM POLYSTYRENE SULFONATE, which is a drug marketed by Ajenat Pharms, Chartwell Rx, Citrusphrma, Cmp Pharma Inc, Epic Pharma Llc, Nuvo Pharms Inc, Pai Holdings Pharm, Upsher Smith Labs, Ani Pharms, Hikma, Lyne, Morton Grove, and Roxane, and is included in thirteen NDAs. It is available from eight suppliers. Additional details are available on the SODIUM POLYSTYRENE SULFONATE profile page.
The generic ingredient in SODIUM POLYSTYRENE SULFONATE is sodium polystyrene sulfonate. There is one drug master file entry for this compound. Eleven suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.
The generic ingredient in SODIUM POLYSTYRENE SULFONATE is sodium polystyrene sulfonate. There is one drug master file entry for this compound. Eleven suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.
Summary for 206815
| Tradename: | SODIUM POLYSTYRENE SULFONATE |
| Applicant: | Chartwell Rx |
| Ingredient: | sodium polystyrene sulfonate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 206815
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SODIUM POLYSTYRENE SULFONATE | sodium polystyrene sulfonate | POWDER;ORAL, RECTAL | 206815 | ANDA | Chartwell RX, LLC | 62135-340 | 62135-340-11 | 10 BOTTLE in 1 BOX (62135-340-11) / 15 g in 1 BOTTLE |
| SODIUM POLYSTYRENE SULFONATE | sodium polystyrene sulfonate | POWDER;ORAL, RECTAL | 206815 | ANDA | Chartwell RX, LLC | 62135-340 | 62135-340-53 | 453.6 g in 1 BOTTLE (62135-340-53) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;ORAL, RECTAL | Strength | 454GM/BOT | ||||
| Approval Date: | Feb 18, 2016 | TE: | AA | RLD: | No | ||||
Complete Access Available with Subscription
